Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 14/20 | 0.56 |
| ▸ | AVPR2 | P30518 | 11/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3457701 | 0.90 | AVPR1A (0.59) | AVPR1AAVPR2LMNAALDH1A1MEN1 | |
| SCHEMBL3454887 | 0.88 | AVPR1A (0.57) | AVPR1AAVPR2LMNAALDH1A1MEN1 | |
| SCHEMBL3456461 | 0.84 | AVPR1A (0.56) | AVPR1AAVPR2LMNAALDH1A1MEN1 | |
| SCHEMBL3454911 | 0.83 | AVPR1A (0.62) | AVPR1AAVPR2LMNAALDH1A1MEN1 | |
| SCHEMBL3454755 | 0.82 | AVPR1A (0.61) | AVPR1AAVPR2LMNAALDH1A1MEN1 | |
| SCHEMBL3455664 | 0.82 | AVPR1A (0.56) | AVPR1AAVPR2LMNAALDH1A1MEN1 | |
| SCHEMBL3459774 | 0.81 | LMNA (0.54) | AVPR1AAVPR2LMNAALDH1A1MEN1 | |
| SCHEMBL3454789 | 0.81 | LMNA (0.58) | AVPR1AAVPR2LMNAALDH1A1MEN1 | |
| SCHEMBL3454873 | 0.80 | AVPR1A (0.55) | AVPR1AAVPR2LMNAALDH1A1MEN1 | |
| SCHEMBL3459953 | 0.80 | AVPR1A (0.59) | AVPR1AAVPR2LMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239012-A2 | Pharmaceutical use of substituted amides | High Point Pharmaceuticals, LLC (US) | 2010-10-13 | — | — | EP | disclosed |
| US-20090264414-A1 | Amide Derivatives and Pharmaceutical Use Thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-20080108598-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2008-05-08 | — | — | US | disclosed |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | disclosed |
| EP-1615698-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108598-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | AVPR1A 935/4885AVPR2 902/4885LMNA 3468/4885 |
| US-20090264414-A1 | Amide Derivatives and Pharmaceutical Use Thereof | HSD11B1, HSD11B2, HSD3B1 | AVPR1A 952/4885AVPR2 835/4885LMNA 3531/4885 |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | AVPR1A 935/4885AVPR2 902/4885LMNA 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.